Security
Integrity Applications Incorporation Com · IGAP
IGAPOTCCommon stockHistorical · closed Aug 13, 2021CIK 1506983Updated Oct 30, 2026
Name history
Integrity Applications, Inc. · through Dec 9, 2021
Current security for this SEC filerGCTK · OTC
IGAP price & chart
Historical security
This listing closed Aug 13, 2021. Live provider charts are shown only for current listings.
Current security: GCTK
About the company
Inc. Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes. Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
In the news
No coverage from other publishers is available.
Recent filings
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other Events
Items 5.03, 8.01, 9.01
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 2.03, 3.02, 7.01, 9.01
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
S-1/A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 8,290,000Source | 826,000Source | 1,495,000Source | 10,210,000Source | 608,000Source | 4,356,000Source | 9,612,000Source | 2,106,000Source | 7,838,000Source | 5,932,000Source | 4,905,000Source | 2,438,000Source |
| Property, Plant and Equipment, NetUSD | 144,000Source | 109,000Source | 95,000Source | 87,000Source | 86,000Source | 116,000Source | 94,000Source | 82,000Source | 138,000Source | 95,000Source | 27,000Source | 40,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,869,000Source | 346,000Source | 1,124,000Source | 9,555,000Source | 159,000Source | 3,929,000Source | 9,100,000Source | 1,497,000Source | 7,383,000Source | 5,617,000Source | 4,492,000Source | 2,312,000Source |
| Assets, CurrentUSD | 8,106,000Source | 642,000Source | 1,381,000Source | 10,077,000Source | 442,000Source | 4,214,000Source | 9,455,000Source | 1,937,000Source | 7,667,000Source | 5,768,000Source | 4,868,000Source | 2,379,000Source |
| Operating Lease, Right-of-Use AssetUSD | 40,000Source | 65,000Source | 19,000Source | 46,000Source | 71,000Source | 26,000Source | 53,000Source | 77,000Source | 33,000Source | 59,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 5,539,000Source | 4,848,000Source | 3,236,000Source | 3,330,000Source | 3,897,000Source | 5,207,000Source | 2,354,000Source | 1,730,000Source | 5,010,000Source | 18,932,000Source | 1,708,000Source | 1,208,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,000Source | 6,000Source | 6,000Source | 1,000Source | 5,000Source | 3,000Source | 26,000Source | 27,000Source | 1,000Source | 1,000Source | 20,000Source | 15,000Source |
| Retained Earnings (Accumulated Deficit)USD | -148,210,000Source | -122,356,000Source | -159,986,000Source | -144,039,000Source | -117,269,000Source | -156,172,000Source | -139,283,000Source | -112,780,000Source | -151,838,000Source | -132,450,000Source | -109,853,000Source | -101,901,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 42,000Source | 5,000Source | 52,000Source | 41,000Source | 22,000Source | 44,000Source | 28,000Source | 22,000Source | 41,000Source | -8,000Source | 16,000Source | 17,000Source |
| Stockholders' Equity Attributable to ParentUSD | 2,751,000Source | -4,022,000Source | -1,741,000Source | 6,880,000Source | -3,289,000Source | -851,000Source | 7,258,000Source | 376,000Source | 2,828,000Source | -13,000,000Source | 3,197,000Source | 1,230,000Source |
| Additional Paid in Capital, Common StockUSD | 150,690,000Source | 118,223,000Source | 158,187,000Source | 150,649,000Source | 113,903,000Source | 155,274,000Source | 146,259,000Source | 113,029,000Source | 151,080,000Source | 119,229,000Source | 112,966,000Source | 103,095,000Source |
| Liabilities and EquityUSD | 8,290,000Source | 826,000Source | 1,495,000Source | 10,210,000Source | 608,000Source | 4,356,000Source | 9,612,000Source | 2,106,000Source | 7,838,000Source | 5,932,000Source | 4,905,000Source | 2,438,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 5,297,000Source | 4,611,000Source | 2,988,000Source | 3,085,000Source | 3,660,000Source | 4,975,000Source | 1,950,000Source | 1,482,000Source | 4,773,000Source | 1,275,000Source | 1,512,000Source | 1,013,000Source |
| Operating Lease, Liability, CurrentUSD | 28,000Source | 25,000Source | 19,000Source | 27,000Source | 25,000Source | 26,000Source | 26,000Source | 24,000Source | 28,000Source | 26,000Source | — | — |
| Accounts Payable, CurrentUSD | 1,709,000Source | 1,857,000Source | 1,116,000Source | 2,644,000Source | 2,736,000Source | 1,299,000Source | 1,612,000Source | 1,014,000Source | 1,317,000Source | 992,000Source | 839,000Source | 672,000Source |
| Operating Lease, Liability, NoncurrentUSD | 12,000Source | 40,000Source | — | 19,000Source | 46,000Source | — | 26,000Source | 53,000Source | 5,000Source | 33,000Source | — | — |
| Other Liabilities, NoncurrentUSD | — | 197,000Source | — | — | 191,000Source | — | — | 195,000Source | 231,000Source | 203,000Source | 196,000Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 325,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 61,000Source | 40,000Source | 211,000Source | 173,000Source | 281,000Source | 439,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -18,000Source | 620,000Source | 325,000Source | 263,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -4,048,000Source | -2,939,000Source | -15,240,000Source | -12,490,000Source | -6,558,000Source | -3,729,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | -9,000Source | -96,000Source | -104,000Source | — | 1,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 9,000Source | 96,000Source | 104,000Source | — | 1,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 591,000Source | 6,395,000Source | 17,043,000Source | 13,743,000Source | 8,730,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,454,000Source | 3,483,000Source | 1,756,000Source | 1,125,000Source | 2,171,000Source | -3,782,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | — | 5,627,000Source | 4,502,000Source | 2,331,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | 28,000Source | 52,000Source | 62,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | 204,000Source | — | — | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | 3,000Source | — | 628,000Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | 22,000Source | 8,000Source | 42,000Source | 36,000Source | 13,000Source | 23,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | 107,000Source | 1,000Source | -3,376,000Source | -3,267,000Source | -798,000Source | — | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | -16,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | -1,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | -4,758,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 1,024,000Source | 1,063,000Source | 1,384,000Source | 1,646,000Source | 2,071,000Source | 1,627,000Source | 6,277,000Source | 4,655,000Source | 2,278,000Source | 2,465,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,171,000Source | -5,087,000Source | -3,814,000Source | -4,756,000Source | -4,334,000Source | -6,833,000Source | -19,388,000Source | -22,597,000Source | -7,097,000Source | -4,435,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -5,087,000Source | — | — | — | — | — | -22,597,000Source | 7,952,000Source | — |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | -131,000Source | -3,335,000Source | -3,298,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 4,309,000Source | 3,251,000Source | 3,400,000Source | 4,796,000Source | 4,203,000Source | 3,498,000Source | 16,090,000Source | 14,547,000Source | 7,104,000Source | 4,432,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 136,000Source | 12,000Source | -414,000Source | -96,000Source | -132,000Source | 4,000Source | 26,000Source | 14,000Source | — | -14,000Source |
| Payments for Repurchase of WarrantsUSD | — | — | 2,000Source | — | — | 65,000Source | — | — | 166,000Source | — | — | — |
| Depreciation and amortization | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -4,309,000Source | -3,251,000Source | -3,400,000Source | -4,796,000Source | -4,203,000Source | -3,498,000Source | -16,090,000Source | -14,547,000Source | -7,104,000Source | -4,432,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 136,000Source | 12,000Source | -414,000Source | -96,000Source | -132,000Source | 4,000Source | 26,000Source | 14,000Source | — | -14,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,171,000Source | -5,087,000Source | -3,814,000Source | -4,756,000Source | -4,334,000Source | -6,833,000Source | -19,388,000Source | -22,597,000Source | -7,097,000Source | -4,435,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 4.64Source | 1,092Source | 0.76Source | 9.62Source | 2.65Source | 40.14Source | 31.22Source | 68.44Source | 0.38Source | 0.29Source |
| Earnings Per Share, DilutedUSD per share | — | — | 4.64Source | 1,092Source | 0.76Source | 9.62Source | 2.65Source | 40.14Source | 31.22Source | 68.44Source | 0.38Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 899,410Source | 4,663Source | 5,009,085Source | 494,504Source | 1,638,128Source | 169,345Source | 621,094Source | 330,171Source | 20,760,266Source | 15,474,660Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 899,410Source | 4,663Source | 5,009,085Source | 494,504Source | 1,638,128Source | 169,345Source | 621,094Source | 330,171Source | 20,760,266Source | — |
| Additional Financial Items | ||||||||||||
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | -4,758,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 1,024,000Source | 1,063,000Source | 1,384,000Source | 1,646,000Source | 2,071,000Source | 1,627,000Source | 6,277,000Source | 4,655,000Source | 2,278,000Source | 2,465,000Source |
| Interest ExpenseUSD | — | — | — | 5,000Source | — | — | — | — | — | 44,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -5,087,000Source | — | — | — | — | — | -22,597,000Source | 7,952,000Source | — |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | -131,000Source | -3,335,000Source | -3,298,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 4,309,000Source | 3,251,000Source | 3,400,000Source | 4,796,000Source | 4,203,000Source | 3,498,000Source | 16,090,000Source | 14,547,000Source | 7,104,000Source | 4,432,000Source |
| Other ExpensesUSD | — | — | — | 18,000Source | — | — | — | — | — | 17,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 3,165,000Source | 2,063,000Source | 2,016,000Source | 3,150,000Source | 2,132,000Source | 1,871,000Source | 9,813,000Source | 9,499,000Source | 4,704,000Source | 1,967,000Source |
| Selling and Marketing ExpenseUSD | — | — | — | — | — | — | — | 128,000Source | — | — | 122,000Source | — |
| Depreciation, Depletion and Amortization, Nonproduction | — | — | — | — | — | — | — | —Source | — | — | — | — |
Offerings
Registration 333-299000
Registration 333-290587
Registration 333-292695
Filing attachments
ex99-1.htm · 8-K · 2026-10-28
Exhibit 99.1 unaudited pro forma financial information On July 14, 2026 (the “Closing Date”), Glucotrack, Inc., a Delaware corporation (“Glucotrack”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Glucotrack Merger Sub, Inc., a Nevada corporation (“Merger Sub”), Lokahi Therapeutics, Inc., a Nevada corporation (“Lokahi”), Glucotrack Technologies Inc. (“Operating Sub”), and Paul V. Goode, solely in his capacity as representative for the Operating Sub (the “Operating …
Read attachment ↗ex4-1.htm · 8-K · 2026-10-22
Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION N…
Read attachment ↗ex4-2.htm · 8-K · 2026-10-22
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRAN…
Read attachment ↗ex4-3.htm · 8-K · 2026-10-22
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-22
Exhibit 99.1 Glucotrack, Inc. Announces Reverse Stock Split 1-for-2 reverse stock split to become effective as of the opening of trading on October 26, 2026 RUTHERFORD, N.J., and LA JOLLA, C.A., October 22, 2026 - Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a healthcare technology and biopharmaceutical company operating Lōkahi Therapeutics™, today announced that it will effect a 1-for-2 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common s…
Read attachment ↗ex4-1.htm · 8-K · 2026-10-19
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRAN…
Read attachment ↗